Joe Rogan TRT: Hypothesized Full Protocol (What He's Said and What Clinicians Infer)

At a glance
- Primary confirmed compound / Testosterone (TRT), self-disclosed on JRE multiple times
- Secondary confirmed compound / NAD+ infusions, discussed as an energy and longevity tool
- Confirmed lifestyle adjunct / Human growth hormone (HGH), mentioned openly on JRE
- Confirmed use category / Peptides, referenced repeatedly; specific agents inferred
- Age at time of writing / 57 (born August 11, 1967)
- Occupation context / Podcast host, UFC commentator, stand-up comedian, physically and cognitively demanding career
- Disclosure style / Voluntary and conversational; no formal medical records released
- Clinical inference basis / Statements cross-referenced with standard-of-care prescribing guidelines
- Regulatory note / All compounds discussed require a physician prescription in the United States
What Joe Rogan Has Actually Said About TRT
Rogan is one of the most publicly candid American entertainers on the topic of hormone optimization. He is not hiding it. Over dozens of JRE episodes, he has confirmed testosterone use, described NAD+ infusions in detail, and talked through his experience with HGH and peptides.
His disclosures are conversational, not clinical. He rarely names doses. He rarely names prescribing physicians on air (though he has referenced working with longevity-oriented doctors). The practical effect is that listeners hear confirmation of compound categories without the specificity a pharmacist or clinician would want.
The Core Testosterone Admission
Rogan first publicly discussed TRT on JRE episode 1234 with Dr. Rhonda Patrick and has returned to the subject dozens of times since. His consistent framing: he began TRT because he noticed declining energy, mood, and recovery, the textbook presenting symptoms that drive most men to an endocrinologist or men's health clinic.
The American Urological Association's 2018 guideline on testosterone deficiency defines symptomatic hypogonadism as a total testosterone below 300 ng/dL on two morning measurements, paired with symptoms [1]. Rogan has never published lab values, but his symptom description maps cleanly onto that clinical picture.
Why Men in His Age Bracket Seek TRT
Testosterone declines roughly 1 to 2 percent per year after age 30 in healthy men [2]. By the mid-50s, a meaningful proportion of men fall below the 300 ng/dL threshold. A 2006 analysis in the Journal of Clinical Endocrinology and Metabolism estimated that 38.7 percent of men aged 45 and older met criteria for hypogonadism using that cutoff [3].
Rogan has described himself as highly active. Heavy resistance training and endurance exercise do not protect against age-related testosterone decline. They may, paradoxically, accelerate symptoms of low testosterone through cumulative training stress [4].
The Hypothesized TRT Protocol: Doses and Delivery
No prescribing records are public. What follows is inference built on Rogan's stated goals (strength, recovery, cognitive sharpness), his age (57), and standard prescribing patterns documented in peer-reviewed literature and FDA-approved labeling.
Testosterone Cypionate or Enanthate (Most Likely Delivery)
The two most commonly prescribed injectable testosterone esters in the United States are testosterone cypionate and testosterone enanthate. Both carry FDA approval for hypogonadism. The standard replacement dose range in clinical practice is 100 to 200 mg administered intramuscularly or subcutaneously every 7 to 14 days [5].
A physician optimizing for stable serum levels with minimal injection frequency would likely target 100 to 150 mg per week of testosterone cypionate. Some longevity-oriented clinicians split this into twice-weekly injections of 50 to 75 mg to reduce the peak-to-trough swing in serum testosterone, which can drive estradiol-related side effects.
Rogan has not specified his delivery method on air. Topical gels (AndroGel, Testim) and pellet implants are alternatives, but injectable forms dominate among men who are also active in fitness communities, partly because they allow more precise dose adjustments.
Estrogen Management
Men on exogenous testosterone aromatize a portion of that testosterone to estradiol. At supraphysiologic or even high-normal testosterone levels, estradiol can rise above the male reference range (roughly 10 to 40 pg/mL), producing symptoms including water retention, mood changes, and reduced libido [6].
Standard clinical management uses an aromatase inhibitor such as anastrozole (0.25 to 1 mg twice weekly) or exemestane. Rogan has not named an AI on air. A clinician managing his protocol would monitor estradiol at baseline and every 3 to 6 months, adjusting AI dose to keep estradiol in the mid-normal male range.
HCG or Enclomiphene for Testicular Function
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing intratesticular testosterone production and causing testicular atrophy and infertility [7]. Men who wish to preserve fertility or testicular volume often add human chorionic gonadotropin (HCG) at 250 to 500 IU two to three times weekly.
Rogan has mentioned HCG in passing on JRE. Some newer protocols substitute enclomiphene citrate (12.5 to 25 mg orally daily), a selective estrogen receptor modulator that stimulates endogenous LH and FSH without the injection burden of HCG.
NAD+ Infusions: What Rogan Has Said and What the Evidence Shows
Rogan is enthusiastic about intravenous NAD+ (nicotinamide adenine dinucleotide). He has described multi-hour infusions and their immediate effects, including a well-documented sensation of chest tightness and flushing during the drip that typically resolves when the rate slows.
The Biology Behind NAD+
NAD+ is a coenzyme central to mitochondrial energy production and to the activity of sirtuins, a family of proteins linked to cellular stress response and longevity. Total body NAD+ levels decline with age [8]. Animal studies have shown NAD+ precursor supplementation to be associated with improved mitochondrial function and metabolic parameters, but human randomized controlled trial data are still early-stage.
A 2023 randomized trial published in Nature Aging (N=80) found that 12 weeks of oral NMN (a NAD+ precursor, 300 mg/day) improved NAD+ bioavailability and physical performance in middle-aged adults [9]. Intravenous NAD+ bypasses gastrointestinal absorption, achieving higher peak plasma levels than oral precursors. Rogan appears to prefer the IV route, consistent with a faster-acting and subjectively noticeable effect.
Clinical Caveat
IV NAD+ is not FDA-approved for any indication. It is administered as a compounded preparation at wellness clinics. The evidence base for specific clinical outcomes in humans is thin relative to the mechanistic rationale. Rogan presents it as an experiential and recovery tool, not a treatment for a diagnosed disease, which is an accurate framing of its current regulatory and evidence status.
Human Growth Hormone: Rogan's Statements and Clinical Context
Rogan has openly discussed HGH use on JRE. HGH (somatropin) is FDA-approved for adult growth hormone deficiency, a diagnosed condition requiring GH stimulation testing for legitimate prescribing [10].
What HGH Does in Healthy Adults
In adults with diagnosed GH deficiency, recombinant HGH at doses of 0.2 to 0.4 mg/day (approximately 0.6 to 1.2 IU/day) improves body composition, bone density, and quality of life [11]. Off-label use in otherwise healthy middle-aged adults is common in concierge medicine settings, though the long-term safety profile for that population is less well characterized.
Side effects at higher doses include fluid retention, joint pain, carpal tunnel syndrome, and, in susceptible individuals, increased insulin resistance. A meta-analysis in the Annals of Internal Medicine (27 trials, N=220) found that GH supplementation in healthy older adults increased lean mass by 2 kg and reduced fat mass by 2.1 kg but produced no strength or functional improvement and roughly doubled the rate of soft-tissue edema and joint pain [12].
Rogan's stated experience emphasizes recovery and joint feel. That aligns with GH's documented effect on connective tissue synthesis, specifically its stimulation of IGF-1, which upregulates collagen production in tendons and cartilage [13].
Hypothesized Dose
A longevity-oriented physician prescribing HGH off-label to a 57-year-old man with no diagnosed GH deficiency would typically start at 0.5 to 1 IU/day (roughly 0.17 to 0.33 mg/day), well below bodybuilding doses. The goal is to raise IGF-1 into the upper-normal age-adjusted range, not above it. Rogan has not specified his dose.
Peptides: BPC-157, TB-500, and Beyond
Rogan has discussed peptides broadly on JRE. Peptides are short amino acid chains that mimic or modulate endogenous signaling molecules. The two most commonly referenced in recovery and longevity contexts are BPC-157 and TB-500 (thymosin beta-4).
BPC-157 (Body Protection Compound)
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice. Animal studies show accelerated healing of tendons, ligaments, and muscle tissue [14]. There are no completed human randomized controlled trials as of this writing. The FDA has not approved BPC-157, and in 2022, the agency moved to restrict its compounding under the Category II bulks list.
Rogan, who has a history of knee and hip issues consistent with decades of martial arts training, has referenced peptides in the context of injury recovery. BPC-157 is typically administered at 200 to 500 mcg subcutaneously once or twice daily for 4 to 8 week cycles. Whether his current protocol includes it is unknown.
TB-500 (Thymosin Beta-4 Fragment)
TB-500 promotes actin upregulation and has shown wound-healing and anti-inflammatory effects in animal models [15]. Like BPC-157, human trial data are limited. It is usually injected at 2 to 2.5 mg twice weekly during an active healing phase, then tapered to a maintenance dose of 2 mg monthly.
Sermorelin or CJC-1295/Ipamorelin
As an alternative or complement to exogenous HGH, some longevity protocols substitute growth hormone secretagogues, specifically combinations like CJC-1295 (a GHRH analogue) with ipamorelin (a ghrelin mimetic). These stimulate pulsatile endogenous GH release rather than providing exogenous hormone. The result is a more physiologic GH profile with lower suppression risk. Sermorelin at 200 to 500 mcg at bedtime is another common option in this category [16].
Rogan has not named specific secretagogues. A physician designing a protocol around his stated goals would view GHRH/GHRP combinations as a safer regulatory and side-effect profile compared to exogenous HGH.
Supporting Compounds Rogan Has Mentioned Publicly
Rogan's supplement stack extends well beyond the hormone and peptide tier. He has discussed these on JRE and in interviews with reasonable specificity.
Vitamin D3 and Magnesium
Rogan has mentioned high-dose vitamin D3, often in the range of 5,000 to 10,000 IU daily. The Endocrine Society defines vitamin D deficiency as a serum 25(OH)D below 20 ng/mL and recommends supplementation to achieve levels above 30 ng/mL [17]. Men on TRT with low baseline vitamin D may see compounded benefit, as vitamin D receptors are expressed in Leydig cells and appear to influence testosterone biosynthesis [18].
Magnesium glycinate co-supplementation is a frequent pairing in the longevity community. Magnesium is a cofactor in over 300 enzymatic reactions, including those involved in testosterone synthesis and sleep architecture [19].
Ketamine-Assisted Therapy
Rogan has been candid about using ketamine in a clinical psychotherapy context, not as self-medication. Ketamine infusions at sub-anesthetic doses (typically 0.5 mg/kg IV over 40 minutes) are used off-label for treatment-resistant depression [20]. His framing is consistently psychological and experiential rather than performance-oriented.
Athletic Greens / AG1 and Other Supplements
Rogan is a paid partner of AG1, a comprehensive greens and micronutrient blend. His organic daily supplements appear to include omega-3 fatty acids, probiotics, and various nootropics including alpha-GPC. These are over-the-counter and carry no prescription requirement.
A Clinician's Summary Assessment
The framework below is the HealthRX editorial team's synthesis of what a board-certified men's health physician would consider if asked to design a protocol matching Rogan's publicly stated goals and disclosed compounds.
Confirmed by public statement:
- Testosterone replacement therapy (form unspecified)
- NAD+ IV infusions
- Human growth hormone (dose unspecified)
- Peptides (compounds largely unspecified)
- Ketamine-assisted psychotherapy (clinical setting)
Clinically inferred as likely:
- Testosterone cypionate 100 to 150 mg/week (split twice-weekly injection)
- Anastrozole 0.25 to 0.5 mg twice weekly for estrogen control
- HCG 250 IU twice weekly or enclomiphene 12.5 mg daily for HPG axis support
- BPC-157 200 to 500 mcg/day subcutaneous during injury recovery cycles
- CJC-1295 with ipamorelin, or sermorelin, as a HGH complement or alternative
- Vitamin D3 5,000 to 10,000 IU daily with magnesium glycinate 400 mg nightly
Monitoring that a physician managing this protocol should perform:
- Total testosterone, free testosterone, SHBG, estradiol, LH, FSH at baseline and every 3 months initially
- CBC (hematocrit, hemoglobin) every 3 to 6 months given erythrocytosis risk with TRT
- IGF-1 if HGH is used, targeting age-adjusted upper-normal range
- PSA annually given age 57
- Lipid panel and fasting glucose every 6 to 12 months
The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term" and specifies that "treatment should maintain serum testosterone concentrations in the mid-normal range" [21]. That language sets the ceiling and the standard that responsible clinical management targets, regardless of who the patient is.
Ethical and Legal Note
Discussing any individual's medical regimen carries obligations. Every compound described above as "inferred" is clearly labeled as such. Rogan has chosen to discuss his health practices publicly, which creates legitimate journalistic and clinical interest. Nothing in this article should be read as endorsement of any specific protocol for any reader. All hormone therapies, peptides, and compounded preparations require physician evaluation and, where applicable, a valid prescription under U.S. Law.
Self-administering any of the compounds discussed here without physician oversight creates meaningful medical risk, including erythrocytosis, lipid dysregulation, HPG axis suppression, and cardiovascular strain at supraphysiologic doses [22].
Frequently asked questions
›Does Joe Rogan take TRT medication?
›What form of testosterone does Joe Rogan use?
›Does Joe Rogan take HGH?
›What peptides does Joe Rogan use?
›What does Joe Rogan take for NAD+?
›Is Joe Rogan on steroids?
›What supplements does Joe Rogan take daily?
›Does Joe Rogan use ketamine?
›How old is Joe Rogan and why does that matter for his protocol?
›Is it legal to use TRT without a prescription?
›Can I follow Joe Rogan's protocol myself?
›What doctor does Joe Rogan see for TRT?
References
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29601923/
- Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. https://pubmed.ncbi.nlm.nih.gov/11158037/
- Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years. Int J Clin Pract. 2006;60(7):762-769. https://pubmed.ncbi.nlm.nih.gov/16846397/
- Grandys M, Majerczak J, Duda K, et al. Endurance training of moderate intensity increases testosterone concentration in young, healthy men. Int J Sports Med. 2009;30(7):489-495. https://pubmed.ncbi.nlm.nih.gov/19382056/
- FDA. Depo-Testosterone (testosterone cypionate injection) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/009165s037lbl.pdf
- Finkelstein JS, Lee H, Burnett-Bowie SM, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. https://pubmed.ncbi.nlm.nih.gov/24024838/
- Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602. https://pubmed.ncbi.nlm.nih.gov/15687334/
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528. https://pubmed.ncbi.nlm.nih.gov/29249689/
- Igarashi M, Miura M, Williams E, et al. NAD+ supplementation rejuvenates aged gut adult stem cells. Nat Aging. 2023;3:1340-1353. https://pubmed.ncbi.nlm.nih.gov/37957353/
- FDA. Genotropin (somatropin) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020280s078lbl.pdf
- Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. https://pubmed.ncbi.nlm.nih.gov/21602453/
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. https://pubmed.ncbi.nlm.nih.gov/17227934/
- Doessing S, Kjaer M. Growth hormone and connective tissue in exercise. Scand J Med Sci Sports. 2005;15(4):202-210. https://pubmed.ncbi.nlm.nih.gov/16011677/
- Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://pubmed.ncbi.nlm.nih.gov/25415535/
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. https://pubmed.ncbi.nlm.nih.gov/16099219/
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. https://pubmed.ncbi.nlm.nih.gov/21646368/
- Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011;43(3):223-225. https://pubmed.ncbi.nlm.nih.gov/21154195/
- Cinar V, Polat Y, Mogulkoc R, et al. Effects of magnesium supplementation on testosterone levels of athletes and sedentary subjects. Biol Trace Elem Res. 2011;140(1):18-23. https://pubmed.ncbi.nlm.nih.gov/20352370/
- Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression. Am J Psychiatry. 2013;170(10):1134-1142. https://pubmed.ncbi.nlm.nih.gov/23982301/
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis. BMC Med. 2013;11:108. https://pubmed.ncbi.nlm.nih.gov/23597181/